Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.

摘要: Patients with localized breast cancer have a 5-year survival rate > 99% compared to patients metastatic (MBC) that rate of ~ 27%. Unregulated PI3K/AKT signaling is common characteristic of MBC, making it desirable therapeutic target for tumors activating mutations in this pathway. Interestingly, inhibition the pathway can affect immune cells, which could potentially alter phenotype undergoing therapy these drugs. The purpose study evaluate how PI3K affects cells MBC during treatment. We investigated effects on cell populations peripheral blood enrolled 4 different clinical trials utilizing inhibitors. Peripheral was drawn at points patient treatment cycles record fluctuations response therapy. who responded positive fold-change cytotoxic T population, had an average duration 31.4 months. In contrast, negative T-cell 5 months. These data suggest more robust, initial anti-tumor may longer do not response. results highlight potential sensitize checkpoint inhibitors, thus providing additional options MBC.